The speaker likes the stock but advises against a large allocation ('don't think you should have your full portfolio in it'), suggesting it is a speculative, cautiously bullish idea.

A high-conviction, long-term bullish pick based on a contrarian bet that its drug could be a 'surprise' success, despite general market skepticism. The $300 target is described as speculative.

The speaker is long the stock ('still on SPRB') and notes it has strong institutional backing, with 'a big chunk of Wall Street' and 'some good investors' buying in.

The speaker is bullish, has bought a small position, and frames it as a long-term play that could take two years to work out, depending on FDA approval and manufacturing.

The speaker is extremely bullish, citing a promising drug acquired from BioMarin, a well-understood ERT business model, strong clinical data, and significant upside potential compared to its current valuation.

Highlighted by investor Martin Shkreli, leading to a massive 1,400% price surge. The investment thesis is a high-risk, high-reward bet on the approval of its lead drug, which is expected to become the new standard of care.

The speaker is very bullish, believing the stock is 'still really cheap' and 'tantalizing' even after a 7x gain, and sees a potential path to a $1 billion market cap.

Extremely bullish thesis based on strong clinical data and a high probability of accelerated FDA approval. The speaker calls it a 'slam dunk' and believes it could become a billion-dollar company.